Detalles de la búsqueda
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38507751
2.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657462
3.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858723
4.
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Br J Cancer
; 125(5): 679-686, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34158598
5.
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Breast Cancer Res Treat
; 188(1): 179-190, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33641083
6.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120223
7.
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 52, 2020 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32434589
8.
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 4, 2020 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31924241
9.
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Oncologist
; 25(2): e214-e222, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043771
10.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28581356
11.
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Breast Cancer Res Treat
; 180(3): 647-655, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32060783
12.
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Breast Cancer Res Treat
; 184(1): 161-172, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32789591
13.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717303
14.
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Breast Cancer Res Treat
; 176(2): 303-310, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31004299
15.
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Future Oncol
; 15(23): 2673-2686, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31305131
16.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
N Engl J Med
; 372(2): 134-41, 2015 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25564897
17.
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Breast Cancer Res Treat
; 170(3): 547-557, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29675680
18.
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Oncologist
; 22(3): 245-254, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28220020
19.
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat
; 165(2): 329-341, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612225
20.
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Breast Cancer Res Treat
; 164(3): 649-658, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28508185